Evaluation of Cellular and Molecular Mechanism of Anti-Asthmatic Effects of A Traditional Herbal Drug In Rats
The present study was performed to ascertain the therapeutic effects/aspects of Lychnis coronaria in ovalbumin (OVA) induced model of bronchial asthma in rats. Wistar rats were immunized with ovalbumin adsorbed on toaluminium hydroxide on day 0 followed by challenge with OVA on day 14 to experimentally induce/simulate bronchial asthma. Lychnis coronaria (1.5 mg/kg, 3 mg/kg and 6 mg/kg) was administered (orally) daily for 14 days and its effects on airway hyper responsiveness to spasmogen and airway inflammation were assessed. Enhanced pause (p-enh), a marker of airway hyper responsiveness, was measured in response to different doses of inhaled methacholine using whole body plethysmography, following which rats were anaesthetized and blood and bronchoalveolar lavage fluid (BALF) were collected and analyzed for OVA specific IgE, pro-inflammatory cytokine (TNF-α) and the Th-2 cytokine (IL-4). Results showed that OVA sensitization and challenge rats increased enhanced pause (P-enh) in response to different doses of methacholine as measured by whole body plethysmography. Assay of blood and BALF showed increased IgE, TNF-αand IL-4 levels as well as in OVA immunized + challenged rats compared to that of normal control rats thus validating the experimental model. Administration of Lychnis coronariafor 14 days induced dose-dependent reductions in p-enh values, as well as levels of OVA specific IgE, TNF-α and IL-4 as compared to that in the vehicle treated Disease control group. The result with prednisolone (10 mg/kg, orally) were comparable with Lychnis coronaria on all the parameters tested. The results showed anti-asthmatic effects of Lychnis coronaria via reducing bronchial hyper responsiveness as well as cellular and molecular markers of airway inflammation and immunity and thus, validating the therapeutic benefits of this Indian traditional medicinal plant for bronchial asthma
2. Chaudhary S, Gulati K, Rai N, Ray A. Evaluation of Anti-Inflammatory and Immunomodulatory Effects of Aqueous Extract of Solanum Xanthocarpum in Experimental Models of Bronchial Asthma. EC Pharmacology and Toxicology, 2016; 2(6):241-250.
3. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn E, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma and Clinical Immunology, 2013; 9(1):9-30.
4. Govind P. Medicinal plants against liver disease. International Journal of Pharmacy Research, 2011; 2(5):115-21.
5. Anonymus A. The Wealth of India, Publication & Information Directorate, Council of Scientific and Industrial Research, 1972; 6:186:1962.
6. Masoodi MH, Khan SA, Shah MY, Verma A. Anti-hepatotoxic activity of Lychnis coronaria in carbon tetrachloride induced toxicity. Journal of Pharmaceutical Research, 2007; 6(4):190-192.
7. Georgieva Y, Furnadjiev G, Balabanova-Radonova E. Investigation of the action of extracts of the herb (plant) Lychniscoronaria L. on inflamed swellings of the back pads of white rats. Eksperimental in Medicine Morfology, 1982; 21:77-81.
8. Lone PA, Bhardwaj AK. Traditional herbal based disease treatment in some rural areas of Bandipora district of Jammu and Kashmir, India. Asian Journal of Pharmaceutical and Clinical Research, 2013; 6:162-171.
9. Kwasniewski FH, Tavares de lima W, Bakhle YS, Jancar S. Impairment in connective tissue mast cells degranulation in spontaneously hypertensive rats: stimulus dependent resistance. British Journal of Pharmacology, 1998; 124(4):772-778.
10. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. American Journal of Respiratory and Critical Care Medicine, 1997; 156(3):766-775.
11. Vos AP, van Esch BC, Stahl B, Rabet LM, Folkerts G, Nijkamp FP, Garssen J.Dietary supplementation with specific oligosaccharide mixtures decreases parameters of allergic asthma in mice. International Immunopharmacology, 2007; 7(12):1582-1587.
12. Abdureyim S, Amat N, Umar A, Upur H, Berke B, Moore N. Anti-inflammatory, immunomodulatory, and heme oxygenase-1 inhibitory activities of ravannapas, a formulation of uighur traditional medicine, in a ratmodel of allergic asthma. Evidence Based Complementary and Alternative Medicine, 2011; 2011:1-13.
13. Wenzel SE, Covar R. Update in asthma. American Journal of Critical Care and medicine, 2006; 173(7):698
14. Barnes PJ, Pederson S. Efficacy and safety of inhaled corticosteroids in asthma. American Review of Respiratory Disease, 1993; 148(4):S01-S26
15. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest Journal, 1998; 113(3): 587-592
16. McKinley L, Kim J, Blogos GL, Siddiqui J, Remick DG. Reproducibility of a novel model of murine asthma-like pulmonary inflammation. Clinical and Experimental Immunology, 2004; 136(2):224-231.
17. McKinley L, Kim J, Blogos GL, Siddiqui J, Remick DG. Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice. Respiratory Research, 2006; 129(7):1-11.
18. Finkelman FD. Use of unrestrained, single chamber barometric plethysmography to evaluate sensitivity to cholinergic stimulation in mouse models of allergic airway disease. Journal of Allergy and Clinical Immunology, 2008; 121(2):334-335
19. Naqvi M, Choudhry S, Tsai HJ, Thyne S, Navarro D, Nazario S, Rodriguez-Santan JR, Casal J, Torres A, Chapela R, Watson HG, Meade K, Rodriguez-Cintron W, Lenoir M, Avila PC, Burchard EG. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. Journal of Allergy and Clinical Immunology, 2007; 120(1):137-43.
20. Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan CM. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Annals of Allergy and Asthma Immunology, 2005; 95(3):247-53
21. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Journal of Respiratory and Critical Care Medicine, 2000; 162: 2341-2351.
22. Thomas PS. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biology, 2001; 79(2):132-140.
23. Pennings HJ, Kramer K, Bast A, Buurman WA, Wouters EF. Tumour necrosis factor-alpha induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. European Respiratory Journal, 1998; 12:45-49.
24. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends in Molecular Medicine, 2004; 10(10):493–499.
25. Chatila TA, Li N, Garcia-Lloret M, Garcia-Lloret M, Kim HJ, Nel AE. T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. The Journal of Allergy and Clinical Immunology, 2008; 121(4):812–823
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).